Bicalutamide CAS 90357-06-5 API Factory High Quality Advanced Prostate Cancer
Manufacturer Supply with High Purity and Stable Quality
Name: Bicalutamide
CAS: 90357-06-5
Bicalutamide in the treatment of Advanced Prostate Cancer
API High Quality, Commercial Production
Name | Bicalutamide |
Synonyms | N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropionamide |
CAS Number | 90357-06-5 |
CAT Number | RF-API76 |
Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
Molecular Formula | C18H14F4N2O4S |
Molecular Weight | 430.37 |
Storage Temperature | 2-8℃ |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White to Off-White Crystalline Powder |
Identification A | IR: Spectrum of the sample corresponds to that of reference standard |
Identification B | HPLC: The retention time of the major peak of the sample solution corresponds to that of the standard solution |
Identification C | Organic Fluoride Identification |
Solubility | Freely Soluble in Acetone and Tetrahydrofuran, Slightly Soluble in Ethyl Acetate |
Melting Point | 191.0~195.0℃ |
Water Content (by K.F) | ≤0.20% |
Fluoride Content | 15.9%~18.5% |
Loss on Drying | ≤0.50% |
Residue on Ignition | ≤0.10% |
Heavy Metals | ≤10ppm |
Residual Solvents | |
Tetrahydrofuran | ≤0.072% |
Toluene | ≤0.089% |
N-Hexane | ≤0.029% |
Acetone | ≤0.50% |
Ethyl Acetate | ≤0.50% |
Related Substances | |
N,N’-Dimethyl Acetamide | ≤0.109% |
Bicalutamide Aminobenzonitrile | ≤0.10% |
Bicalutamide Related Compound A Isomer A | ≤0.10% |
Bicalutamide Related Compound A Isomer B | ≤0.10% |
Desfluoro Bicalutamide | ≤0.20% |
2-Fluoro Bicalutamide | ≤0.20% |
Deoxy Bicalutamide | ≤0.20% |
Bicalutamide Sulfide | ≤0.10% |
Any Unspecified Impurity | ≤0.10% |
Total Impurities | ≤0.50% |
Particle Size | 90%<10um; 50%<5um |
Assay | 98.0%~102.0% (on the dried basis) |
Microbiological Tests | |
Total Viable Aerobic Count | ≤500CFU/g |
Yeasts and Molds | ≤50CFU/g |
Shelf Life | 24 Months |
Test Standard | Enterprise Standard; USP Standard |
Usage | API, in the treatment of Advanced Prostate Cancer |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Bicalutamide (CAS: 90357-06-5) is a non-steroidal androgen antagonist, which competes androgen receptor with the androgen, blocks cellular uptake of androgen, and inhibits the binding of androgens to the target organ. It binds with the androgen receptor that forms receptor complex, which enters the nucleus and combined with the nucleoprotein, consequently inhibiting tumor cell growth. It can be as a first-line drug for palliative treatment of advanced prostate cancer. Bicalutamide was launched in the United Kingdom, its first worldwide market, for the treatment of advanced prostate cancer in combination with an LHRH analog or surgical castration. A non-steroidal, peripherally selective antiandrogen, bicalutamide inhibits the action of dihydrotestosterone and testosterone at target sites by competitive binding to the cytosolic androgen receptor. It was reportedly well tolerated with no significant cardiovascular and metabolic side effects due to the benefit of lacking any steroid activity. The efficacy of bicalutamide as a monotherapy has been demonstrated clinically. Promising response rates were also reported in treating colorectal, breast, pancreas and non-small cell lung cancers.